Background: Paclitaxel, ifosfamide, cisplatin (TIP) is commonly used as salvage for malignant germ cell tumors (MGCT) in adults; however, additional administration of cisplatin at a young age could cause significant short-and long-term toxicities in a group of patients with high expected salvage.
INTRODUCTION
Cisplatin-based regimens are considered the standard of care in the first line management of patients with malignant germ cell tumors (MGCT); combined with appropriate local control, survival rates in excess of 70-80% are consistently reported. For patients who Abbreviations: CR, complete response; GCT, germ cell tumor; JEB, carboplatin, etoposide, bleomycin; MaGIC, malignant germ cell international collaborative; MGCT, malignant germ cell tumor; PD, progressive disease; PEB, cisplatin, etoposide, bleomycin; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease; TIC, paclitaxel, ifosfamide, carboplatin; TI-CE, paclitaxel, ifosfamide, carboplatin, etoposide; TIP, paclitaxel, ifosfamide, cisplatin; VeIP, vinblastine, ifosfamide, cisplatin relapse, salvage chemotherapy using a cisplatin-containing regimen is appropriate, except for the small subgroup of patients who have platinum refractory disease defined as relapse or progression within 4 weeks from prior cisplatin regimen. In adults, standard-and highdose chemotherapy regimens have demonstrated efficacy and currently there is no consensus on initial salvage approach. Retrospective series seem to indicate the superiority of tandem or triplet transplant for a subgroup of patients with a higher risk of disease progression. [1] [2] [3] Currently a randomized trial Alliance A031102 (TIGER trial) is underway which is randomizing standard-dose chemotherapy versus high-dose chemotherapy with stem cell rescue. 4 The most commonly used standard-dose salvage regimens include a combination of cisplatin plus ifosfamide with paclitaxel (TIP) or vinblastine (VeIP). 5, 6 Given the rarity of the disease and the excellent outcomes using first line therapy in children with MGCT, the reports on salvage therapy for pediatric patients with relapsed GCT are very limited. 7 Although relapsed germ cell tumors may continue to show responsiveness to cisplatin, its continued use is associated with significant short-and long-term toxicities, including ototoxicity, neurotoxicity, nephrotoxicity, and, among adult men, a twofold increase in second malignant neoplasms and risk of cardiovascular disease 8 ; these late effects are particularly relevant in children and adolescents. The cisplatin analog carboplatin is effective in pediatric germ cell tumors with a better safety profile and fewer long-term side effects. The UK Children's Cancer and Leukemia Group has used carboplatin-containing regimens as first line for pediatric germ cell tumors since 1989, and have comparable results to cisplatin-containing regimens. 9 Based on these factors, in the Children's Oncology Group AGCT0521 trial, the TIP regimen was modified and carboplatin was substituted for cisplatin. The endpoint of the trial was response after two cycles. As the role of standard versus high-dose chemotherapy for consolidation was unclear, further therapy was at investigator discretion. Herein we report the results of this study using paclitaxel, ifosfamide, and carboplatin (TIC).
PATIENTS AND METHODS

Eligibility
Children less than 21 years of age with recurrent malignant or chemotherapy-resistant extracranial germ cell tumors were eligible if they had received a first line chemotherapy regimen that included cis- Patients with recurrent GCT previously treated by surgery alone, and patients with pure immature teratoma (any grade), germinoma, or sex cord stromal tumors were not eligible. All patients and/or their parents or legal guardians signed informed consent prior to participation.
Study design and treatment
This was a two stage, Phase II multi-institutional study conducted by the Children's Oncology Group. The primary aim was to evaluate the response rate of recurrent or resistant GCT to the combination of TIC.
Response evaluation was performed after two cycles of chemotherapy, and further treatment (local and systemic therapy) was at the discretion of the treating physicians.
The chemotherapy regimen consisted of paclitaxel 135 mg/m 2 /day on day 1, ifosfamide 1,800 mg/m 2 /dose Days 1-5 with mesna 1,080 mg/m 2 /day divided to three equal doses of 360 mg/m 2 and carboplatin AUC 6.5 Day 1, using the modified Calvert Formula by Marina et al. 10 The maximum dose of carboplatin to be administered did not exceed 560 mg/m 2 . Filgrastim 5 g/kg/dose daily starting on Day 6 until ANC > 1,500/ l post nadir was administered. Criteria to start a cycle was if ANC ≥ 750/ l, and platelets ≥ 75,000/ l. Appropriate antibiotics, blood products, antiemetics, fluids, electrolytes, and general supportive care were used as necessary
Evaluation of response and toxicity
Imaging response was assessed after two cycles using RECIST criteria.
In addition, the study incorporated tumor marker response in patients whose markers were elevated at least 10-fold above normal at study entry. Complete response (CR) was defined as no measurable disease, and normal HCG and normal AFP (if initial AFP was ≤40,000 ng/ml; otherwise appropriate tumor marker decline). Partial response (PR) was defined as at least 30% decrease in tumor burden and for patients with ≥10-fold marker elevation above normal at enrollment, at least a 1 log (90%) reduction. Progressive disease (PD) was defined as increase in tumor measurement by 20% or increase in markers by 1 log. Stable disease (SD) was defined as neither PR or PD. Patients who demonstrated a CR or PR were considered as responders. Assessment of toxicity was done using CTCAE version 4.
Study design
The study was designed as a two-stage design. Ten response-evaluable patients were to be enrolled in the first stage and enrollment was stopped until the response status for these patients could be determined. If three or fewer patients demonstrated CR or PR, enrollment was to be terminated with the conclusion that protocol therapy was not considered sufficiently efficacious for further study. If 4 or more responses were noted in the first stage, 10 more response-evaluable patients were enrolled and study accrual was terminated. If the true response rate was 27%, the probability enrollment would terminate at the end of the first stage was approximately 90%. If the true response rate was 65%, the probability full enrollment of 20 patients would be allowed was 90%. The response rate was estimated accounting for the two-stage design by the UMVUE method of Jung and Kim. 11 Standard deviation (range) 2872.9 (0-12,086)
TA B L E 1 Patient characteristics
All eligible patients who received at least one dose of a protocolspecified agent were to be considered in the analysis of toxicity. The occurrence of each CTC version 4 adverse experience reported as grade 3 or greater at any time during protocol therapy was ascertained.
The proportion of all patients experiencing each of the adverse experiences identified was calculated. are displayed in Table 1 .
RESULTS
AGCT0521 was open between
Response assessment
All 20 patients were assessable for response. After two cycles of TIC, by RECIST criteria alone, 8 patients achieved a partial response (40%), 10 patients had stable disease, and 2 patients had progressive disease.
Seventeen patients had markers ≥10 times above normal and were assessable for marker response. After two cycles, markers had at least a 1 log decline in 10 of the 17 patients (58.8%) ( Table 2 ).
Using study defined response criteria which combined RECIST response and tumor marker decline (Table 2 ), 7 of the 20 patients were considered responders upon completion of two cycles. The estimated response rate accounting for the two-stage design is 44%. All seven patients had partial response by RECIST and their tumor markers had at least a 1 log reduction if elevated greater than 10-fold above normal at enrollment.
Thirteen patients were nonresponders by study defined response criteria. Ten patients met study criteria for stable disease, two had progressive disease and one patient met the RECIST criteria for partial response but that patient's elevated HCG did not achieve a 1 log decline. Of the 10 patients with stable disease, tumor markers at enrollment were elevated ≥10-fold above normal in 8 patients (7 AFP, 1 HCG). Markers had at least a 1 log reduction in 4/8 patients. Both patients with progressive disease had marker elevation at enrollment (one AFP and one HCG) and neither patient's tumor markers showed any decrease during therapy.
Treatment post completion of TIC and outcome
Although the primary endpoint of this study was response to two cycles of TIC, treatment post completion of TIC and outcome were reported in follow-up. 
Toxicity
All 20 patients were evaluable for toxicity. Eighteen patients received both cycles of TIC, whereas 2 patients were taken off therapy after one cycle due to toxicity. One patient was taken off therapy due to nephrotoxicity. The glomerular filtration rate decreased to less than 70 ml/min/1.73m 2 . Despite a 1 week delay the GFR did not increase to above 70 ml/min and patient was taken off protocol. The reason why other patient was taken off therapy is unclear. The major grade 3 and 4 toxicities were myelosuppression, with neutropenia, thrombocytopenia, and anemia seen in 60, 45, and 40% of patients. Febrile neutropenia occurred in 25% of patients. 
TA B L E 2
DISCUSSION
This is the first study evaluating a salvage regimen for relapsed germ cell tumors in children. Our study showed that TIC regimen was effective as second line therapy in children with relapsed germ cell tumors. After two cycles of TIC, the estimated overall response rate was 44% using combined RECIST response and tumor marker decline.
Forty percent of patients achieved a RECIST-defined partial response, and using marker decline alone 58.8% of patients with elevated markers had at least a 1 log (90%) reduction of markers. The incorporation of tumor marker decline to enhance response assessment is particularly important in patients with stable disease, as the residual tumor may be a teratoma, and hence response by imaging alone may be inaccurate.
In adults, the management of relapsed GCT is either with standarddose chemotherapy or high-dose chemotherapy with autologous stem cell rescue. 5, 6, [12] [13] [14] [15] [16] [17] [18] There are no completed randomized trials comparing these two approaches and currently no consensus exists on whether initial salvage should be standard-dose or high-dose chemotherapy. Currently a randomized trial, Alliance A031102 (TIGER trial) is underway which is randomizing standard-dose chemotherapy with TIP versus high-dose chemotherapy with TI-CE 4 The most commonly used standard-dose chemotherapy regimens are ifosfamide and cisplatin with paclitaxel (TIP) or vinblastine (VeIP). 5, 6 The TIP regimen other studies used a lower dose of paclitaxel and reported a favorable response rate of 60-65%. 19, 20 This was attributed to a lower paclitaxel dose.
Our study modified the TIP regimen used in adults, by substituting carboplatin for cisplatin to decrease toxicity. Cisplatin is associated with both short-and long-term toxicities, including ototoxicity, neurotoxicity, nephrotoxicity, and twofold increase in SMN and cardiovascular disease. Carboplatin has a better toxicity profile with fewer short-and long-term side effects, and it has been used as initial therapy for pediatric GCT in the UK since 1989; the outcomes using carboplatin, etoposide, bleomycin (JEB), are comparable to those with cisplatin-based regimens (PEB). 9 Recently the US Children's Oncology Group and the UK Children's Cancer and Leukemia Group JEB) did not show a significant difference in outcome. 21 In addition, high-dose carboplatin is also an integral part of high-dose chemotherapy regimens used for relapse GCT in adults. [12] [13] [14] [15] [16] This provided the rationale for substituting carboplatin for cisplatin in the TIC regimen.
In addition to this substitution, there were several other differences between the TIP and the TIC regimen used in this trial. The dose of paclitaxel used was lower at 135 mg/m 2 per cycle in TIC regimen compared to 250 mg/m 2 per cycle used in TIP, and the ifosfamide dose was higher at 9 g/m 2 /cycle versus 6 g/m 2 /cycle.
It is difficult to compare the response rates between TIP and our study using TIC. In our study response was evaluated after two cycles whereas the response after TIP was evaluated after four cycles. The TIC regimen was well tolerated and there was no neurotoxicity or treatment related death. Similar to the TIP regimen, the major toxicity was myelosuppression with fever and neutropenia reported in 25% of patients. There are few other reports of salvage regimen for relapse MGCT in children. In the French TGM 95 trial, 19 children had refractory or recurrent MGCT. They were treated with surgery and various chemotherapy regimens with 5 year EFS and OS of 26 and 32%, respectively. 7 Our study has some limitations. Due to the rarity of relapse in pediatric MGCT, the study was designed to accrue a small number of patients. It was designed to evaluate response after only two cycles and hence we cannot comment on role of further consolidation therapy. The dose of paclitaxel in our study was lower than used in TIP, and may account for the lower response rate.
In conclusion, the TIC regimen is active in relapse MGCT and should be considered an option for salvage therapy, particularly in younger children and those with preexisting ototoxicity, suggesting that carboplatin could be used as an alternative to cisplatin in the standard TIP regimen. However, conventional dose chemotherapy with TIP or high-dose chemotherapy with TI-CE are currently accepted standard options especially in adolescents and older adults and a current trial is underway randomizing these two approaches.
